These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6285557)

  • 41. Glucantime susceptibility of Leishmania promastigotes under variable growth conditions.
    Moreira ES; Soares RM; Petrillo-Peixoto Mde L
    Parasitol Res; 1995; 81(4):291-5. PubMed ID: 7624285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemistry of Pentostam resistant Leishmania.
    Berman JD; Edwards N; King M; Grogl M
    Am J Trop Med Hyg; 1989 Feb; 40(2):159-64. PubMed ID: 2537584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. American cutaneous leishmaniasis: disappearance of amastigotes from lesions during antimonial therapy.
    Mayrink W; Raso P; Melo MN; Michalick MS; Magalhães PA; Williams P; da Costa CA; Dias M
    Rev Inst Med Trop Sao Paulo; 1983; 25(6):265-9. PubMed ID: 6672988
    [No Abstract]   [Full Text] [Related]  

  • 45. Pentavalent antimonials: new perspectives for old drugs.
    Frézard F; Demicheli C; Ribeiro RR
    Molecules; 2009 Jun; 14(7):2317-36. PubMed ID: 19633606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
    Castro C; Sampaio RN; Marsden PD
    Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
    [No Abstract]   [Full Text] [Related]  

  • 48. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL; Hanson WL; Alving CR; Hendricks LD
    Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relative insensitivity of a Kenyan strain of Leishmania donovani to pentavalent antimony therapy in hamsters.
    Hanson WL; Waits VB; Hendricks LD; Hockmeyer WT; Davidson DE; Chapman WL
    J Parasitol; 1983 Apr; 69(2):446-7. PubMed ID: 6854484
    [No Abstract]   [Full Text] [Related]  

  • 50. Genistein and Ascorbic Acid Reduce Oxidative Stress-Derived DNA Damage Induced by the Antileishmanial Meglumine Antimoniate.
    de Jesus LCL; Soares RP; Moreira VR; Pontes RL; Castelo-Branco PV; Pereira SRF
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime).
    Roberts WL; McMurray WJ; Rainey PM
    Antimicrob Agents Chemother; 1998 May; 42(5):1076-82. PubMed ID: 9593130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Observations on the intravenous toxicity and chelating activity of sodium stibogluconate.
    GREEN J; HICKMAN AC; SHARPE HM; TOMICH EG
    J Pharm Pharmacol; 1957 Dec; 9(12):983-9. PubMed ID: 13492187
    [No Abstract]   [Full Text] [Related]  

  • 53. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil.
    Neal RA; van Bueren J; McCoy NG; Iwobi M
    Trans R Soc Trop Med Hyg; 1989; 83(2):197-8. PubMed ID: 2558433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antileishmaniasis activity of flavonoids from Consolida oliveriana.
    Marín C; Boutaleb-Charki S; Díaz JG; Huertas O; Rosales MJ; Pérez-Cordon G; Guitierrez-Sánchez R; Sánchez-Moreno M
    J Nat Prod; 2009 Jun; 72(6):1069-74. PubMed ID: 19489596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oriental sore. A look at trends in and approaches to the treatment of leishmaniasis.
    Chong H
    Int J Dermatol; 1986 Dec; 25(10):615-23. PubMed ID: 3026976
    [No Abstract]   [Full Text] [Related]  

  • 56. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria.
    Belazzoug S; Neal RA
    Trans R Soc Trop Med Hyg; 1986; 80(4):670-1. PubMed ID: 3544363
    [No Abstract]   [Full Text] [Related]  

  • 57. Leishmania mexicana: chemistry and biochemistry of sodium stibogluconate (Pentostam).
    Berman JD; Grogl M
    Exp Parasitol; 1988 Oct; 67(1):96-103. PubMed ID: 2844580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Soy isoflavones have antimutagenic activity on DNA damage induced by the antileishmanial Glucantime (meglumine antimoniate).
    Cantanhêde LF; Almeida LP; Soares RE; Castelo Branco PV; Pereira SR
    Drug Chem Toxicol; 2015; 38(3):312-7. PubMed ID: 25268948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotoxic effects of the antileishmanial drug Glucantime.
    Lima MI; Arruda VO; Alves EV; de Azevedo AP; Monteiro SG; Pereira SR
    Arch Toxicol; 2010 Mar; 84(3):227-32. PubMed ID: 19911167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.